Impact of Liraglutide 3.0 mg on Metabolic Dysfunction-Associated Steatotic Liver Disease in Individuals with Obesity: A Real-World Study
{{output}}
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD), a prevalent condition, can progress to liver cirrhosis and hepatocellular carcinoma. This study evaluated the efficacy of liraglutide 3.0 mg in treat... ...
